menu
    • menu
    [{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"BVX-0320","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Not Applicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"SARS-CoV-2 s-protein based vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ BioVaxys Technology","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ BioVaxys Technology"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Bio Elpida","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BVX-0918A","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ BioVaxys","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ BioVaxys"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"BVX-0918A","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/ Not Applicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Bio Elpida","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"BVX-0918A","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ BioVaxys Technology","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ BioVaxys Technology"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Dinitrophenyl Modified S-spike Protein of SARS-CoV-1","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Not Applicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"BVX-0320","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ The Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ The Ohio State University"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Deaconess Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Deaconess Research Institute","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/ Deaconess Research Institute"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Procare Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"BVX-0918C","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ Procare Health","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Procare Health"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Bio Elpida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"BVX-0918","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biovaxys \/ BioVaxys Technology Corp","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/ BioVaxys Technology Corp"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Hospices Civils de Lyon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biovaxys \/ Hospices Civils de Lyon","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/ Hospices Civils de Lyon"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Merck Millipore","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"BVX-0320","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ Millipore-Sigma","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Millipore-Sigma"},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"BVX-0320","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ The Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ The Ohio State University"},{"orgOrder":0,"company":"Biovaxys","sponsor":"ProCare Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biovaxys \/ Biovaxys","highestDevelopmentStatusID":"12","companyTruncated":"Biovaxys \/ Biovaxys"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Biovaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"Maveropepimut-S","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biovaxys","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ BioVaxys","highestDevelopmentStatusID":"8","companyTruncated":"Biovaxys \/ BioVaxys"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"BVX-0918","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biovaxys \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Biovaxys \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Biovaxys

    Menu

    Biovaxys

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $0.3 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Biovaxys Announces Closing of Third Tranche of Private Placement

                            Details : The company will advance its discovery, preclinical and clinical assets, including BVX-0918 in oncology, antigen desensitization, and other immunological fields based on the DPX technology.

                            Brand Name : BVX-0918

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 11, 2024

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $0.3 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Immunovaccine Technologies

                            Deal Size : $25.7 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Biovaxys Acquires Intellectual Property and Assets Of Former Imv Inc.

                            Details : The acquisition supplements BioVaxys' cancer vaccine portfolio with DPX-Survivac, a cancer vaccine delivering antigenic peptides from survivin, commonly overexpressed in advanced cancers.

                            Brand Name : DPX-Survivac

                            Molecule Type : Vaccine

                            Upfront Cash : $25.7 million

                            February 12, 2024

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Immunovaccine Technologies

                            Deal Size : $25.7 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid,Coriolus Versicolor

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : ProCare Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps

                            Details : Papilocare (hyaluronic acid) vaginal gel is the first treatment that has been scientifically proven to have a very high success rate in eliminating not only the human papiloma virus (HPV), but also precancerous lesions of the cervix.

                            Brand Name : Papilocare

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 19, 2022

                            Lead Product(s) : Hyaluronic Acid,Coriolus Versicolor

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : ProCare Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : The Ohio State University

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021

                            Details : BVX-1021 is hapten-modified recombinant S1 subunit of the spike protein from the SARS1 virus, whereas BVX-0320, is a hapten-modified recombinant S1 subunit of the spike protein from SARS-CoV-2 ("SARS2"), the virus which causes Covid-19.

                            Brand Name : BVX-1021

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 16, 2022

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : The Ohio State University

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Merck Millipore

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biovaxys Announces Completed Synthesis of Its Pan-sarbecovirus Vaccine Candidate and Launch of in Vivo Animal ...

                            Details : BVX-1021 using a new batch of recombinant SARS-1 protein from the supplier that screened out the extraneous protein aggregate, has been synthesized using the purified SARS1 protein, OSU is now able to complete the neutralizing antibody studies.

                            Brand Name : BVX-1021

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 06, 2022

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Merck Millipore

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Bio Elpida

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study

                            Details : BVX-0918A, BioVaxys’s cancer vaccines are created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic.

                            Brand Name : BVX-0918

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 08, 2022

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Bio Elpida

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Hospices Civils de Lyon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters ...

                            Details : BioVaxys expects to be able to prepare its regulatory submission for a EU Phase I study of BVX-0918 in Stage III/Stage IV ovarian cancer near the end of this year, with vaccine supply for the planned clinical study available early May 2022.

                            Brand Name : BVX-0918

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 18, 2022

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Hospices Civils de Lyon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918C

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Procare Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            International Patent Application Filed for Cervical Cancer Vaccine

                            Details : BioVaxys’s cancer vaccine BVX-0918C, created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into patient to induce an immune response to proteins which are otherwise not immunogenic.

                            Brand Name : BVX-0918C

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : BVX-0918C

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Procare Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Deaconess Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduct...

                            Details : Access to ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918, the Company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer.

                            Brand Name : BVX-0918

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 25, 2022

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Deaconess Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : The Ohio State University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio S...

                            Details : BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviru...

                            Brand Name : BVX-1021

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 17, 2022

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : The Ohio State University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth